CagriSema

Synonimy: Cagrilintide/Semaglutide combination, AM833/Semaglutide, CagriSema

In the competitive landscape of metabolic disease management, combination therapies are drawing significant attention for their potential to achieve greater efficacy than monotherapies. CagriSema, a fixed-dose combination of the long-acting amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, is at the forefront of this trend. It is being developed for obesity and type 2 diabetes, targeting multiple metabolic pathways simultaneously to enhance weight loss and glycemic control.

CagriSema is not a single molecule but a co-formulation of two distinct peptides: cagrilintide (a synthetic analog of human amylin) and semaglutide (a GLP-1 analog). Both peptides are engineered for prolonged action, allowing for once-weekly subcutaneous administration. The combination leverages complementary mechanisms: semaglutide enhances insulin secretion and suppresses appetite, while cagrilintide slows gastric emptying and promotes satiety. This dual approach may offer superior clinical outcomes compared to either agent alone.

From a manufacturing perspective, CagriSema is produced via solid-phase peptide synthesis (SPPS) and subsequent purification. Each peptide is synthesized separately, then combined in a fixed ratio (typically 1:1 by weight) to create the final drug product. The complexity of the synthesis requires stringent quality control, and our product is supplied as a high-purity lyophilized powder, suitable for research and further formulation development. With the rising demand for effective anti-obesity medications, CagriSema represents a promising candidate for pharmaceutical companies aiming to expand their metabolic portfolio.

Product Overview & Composition

CagriSema is a combination of two synthetic peptides: cagrilintide and semaglutide. Cagrilintide is a long-acting amylin analog with a fatty acid side chain that promotes albumin binding and extends half-life. Semaglutide is a GLP-1 analog with similar modifications, enabling once-weekly dosing. The combination is formulated to mimic the body’s natural satiety signals while enhancing insulin sensitivity.

Each peptide is produced under cGMP conditions and undergoes rigorous analytical testing to ensure identity, purity, and potency. The final product is a sterile, lyophilized powder that can be reconstituted for injection. Our CagriSema is intended for research use only and is not for human consumption.

Key Applications

• Obesity research: Investigating synergistic effects of amylin and GLP-1 receptor activation on weight loss.
• Type 2 diabetes studies: Evaluating improvements in glycemic control and insulin sensitivity.
• Metabolic syndrome: Exploring impact on lipid profiles, blood pressure, and cardiovascular risk factors.
• Combination therapy development: Serving as a benchmark for other dual-agonist approaches.
• Pharmacokinetic studies: Assessing absorption, distribution, and elimination of co-administered peptides.
• Preclinical models: Testing in rodent and non-human primate models of obesity and diabetes.

Quality & Standards

Packaging & Supply

• Opakowanie: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g in sterile glass vials with rubber stoppers and aluminum seals.
• MOQ: 10 mg
• Czas realizacji: 3–5 dni roboczych (towary dostępne w magazynie)
• Dokumentacja: COA, MSDS, TDS, and HPLC chromatogram provided with each shipment.
• Przechowywanie: Store at -20°C, protected from light and moisture.

Zapytanie ofertowe

• LyvBio Sp. z o.o. — E-mail: info@lyvbio.com